Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration
In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of au...
| Format: | eBook |
|---|---|
| Language: | English |
| Published: |
Basel
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Subjects: | |
| Online Access: | Open Access: DOAB: description of the publication Open Access: DOAB, download the publication |
| LEADER | 04401namaa2201237uu 4500 | ||
|---|---|---|---|
| 001 | doab81005 | ||
| 003 | oapen | ||
| 005 | 20220506 | ||
| 006 | m o d | ||
| 007 | cr|mn|---annan | ||
| 008 | 220506s2022 xx |||||o ||| 0|eng d | ||
| 020 | |a 9783036539294 | ||
| 020 | |a 9783036539300 | ||
| 020 | |a books978-3-0365-3929-4 | ||
| 024 | 7 | |a 10.3390/books978-3-0365-3929-4 |2 doi | |
| 040 | |a oapen |c oapen | ||
| 041 | 0 | |a eng | |
| 042 | |a dc | ||
| 072 | 7 | |a M |2 bicssc | |
| 720 | 1 | |a Kodjikian, Laurent |4 edt | |
| 720 | 1 | |a Kodjikian, Laurent |4 oth | |
| 245 | 0 | 0 | |a Diagnosis, Treatment and Prevention of Age-Related Macular Degeneration |
| 260 | |a Basel |b MDPI - Multidisciplinary Digital Publishing Institute |c 2022 | ||
| 300 | |a 1 online resource (246 p.) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 506 | 0 | |a Open Access |f Unrestricted online access |2 star | |
| 520 | |a In this reprint, we hope to review the basics and highlight the latest developments in AMD. This demonstrates the benefits of the international scientific community working on this disease, to limit its negative impacts, the most vital of which is the loss of visual function, leading to a loss of autonomy and a decrease in patients' quality of life. | ||
| 540 | |a Creative Commons |f https://creativecommons.org/licenses/by/4.0/ |2 cc |u https://creativecommons.org/licenses/by/4.0/ | ||
| 546 | |a English | ||
| 650 | 7 | |a Medicine and Nursing |2 bicssc | |
| 653 | |a aflibercept | ||
| 653 | |a aflibercept monotherapy | ||
| 653 | |a age-related macular degeneration | ||
| 653 | |a age-related macular degeneration (AMD) | ||
| 653 | |a AMD | ||
| 653 | |a angiogenesis | ||
| 653 | |a anti-vascular endothelial growth factor | ||
| 653 | |a anti-vascular endothelial growth factor | ||
| 653 | |a anti-VEGF | ||
| 653 | |a anti-VEGF treatment | ||
| 653 | |a AREDS2-HOME study | ||
| 653 | |a arterial hypertension | ||
| 653 | |a bevacizumab | ||
| 653 | |a brolucizumab | ||
| 653 | |a cardiovascular risk factors | ||
| 653 | |a cataract surgery | ||
| 653 | |a choriocapillaris | ||
| 653 | |a choroidal neovascularisation | ||
| 653 | |a choroidal neovascularization | ||
| 653 | |a clinical trials | ||
| 653 | |a comparative therapies | ||
| 653 | |a Delphi | ||
| 653 | |a disease activity | ||
| 653 | |a effectiveness | ||
| 653 | |a emerging treatment | ||
| 653 | |a epithelial tear | ||
| 653 | |a exudation | ||
| 653 | |a fellow eye | ||
| 653 | |a food supplement | ||
| 653 | |a ForeseeHome AMD Monitoring System® | ||
| 653 | |a good baseline visual acuity | ||
| 653 | |a hereditary retinal dystrophy | ||
| 653 | |a identification | ||
| 653 | |a intravitreal anti-vascular endothelial growth factor | ||
| 653 | |a lifestyle | ||
| 653 | |a long-term FU | ||
| 653 | |a macula-off rhegmatogenous detachment | ||
| 653 | |a macular neovascularization | ||
| 653 | |a meta-analysis | ||
| 653 | |a meta-regression | ||
| 653 | |a meteorin | ||
| 653 | |a n/a | ||
| 653 | |a neovascular age-related macular degeneration | ||
| 653 | |a neovascular age-related macular degeneration (nAMD) | ||
| 653 | |a nutrients | ||
| 653 | |a oct-angiography | ||
| 653 | |a optical coherence tomography | ||
| 653 | |a optical coherence tomography angiography | ||
| 653 | |a polypoidal choroidal vasculopathy | ||
| 653 | |a prevention | ||
| 653 | |a pro re nata regimen | ||
| 653 | |a quiescent macular neovascularization | ||
| 653 | |a ranibizumab | ||
| 653 | |a reading acuity | ||
| 653 | |a real-world evidence | ||
| 653 | |a retina | ||
| 653 | |a retinal deep perifoveal capillary plexus | ||
| 653 | |a risk | ||
| 653 | |a Sorsby | ||
| 653 | |a Sorsby's fundus dystrophy | ||
| 653 | |a STARS® | ||
| 653 | |a superficial perifoveal capillary plexus | ||
| 653 | |a switch therapy | ||
| 653 | |a therapeutic innovation | ||
| 653 | |a treat and extend | ||
| 653 | |a treat-and-extend | ||
| 653 | |a treatment change | ||
| 653 | |a treatment outcome | ||
| 653 | |a treatment-naive | ||
| 653 | |a Vascular Endothelial Growth Factor (VEGF) | ||
| 653 | |a visual acuity | ||
| 793 | 0 | |a DOAB Library. | |
| 856 | 4 | 0 | |u https://directory.doabooks.org/handle/20.500.12854/81005 |7 0 |z Open Access: DOAB: description of the publication |
| 856 | 4 | 0 | |u https://mdpi.com/books/pdfview/book/5347 |7 0 |z Open Access: DOAB, download the publication |